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SARS-CoV-2 immunochromatographic IgM/IgG rapid test
in pregnancy: A false friend?
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Abstract
Background: An increasing body of evidence has revealed that SARS-CoV-2 infection in pregnant women could
increase the risk of adverse maternal and fetal outcomes. Careful monitoring of pregnancies with COVID-19 and
measures to prevent neonatal infection are warranted. Therefore, rapid antibody tests have been suggested as an
efficient screening tool during pregnancy.
Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay
for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients
during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromato-
graphic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent
microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgMþIgA antibodies as the gold standard.
We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a
significantly lower diagnostic performance than reported in non-pregnant patients.
Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable
screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in
pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies
must be verified by other test in pregnant patients.
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Introduction
Pregnant women and their fetuses represent a high-risk
population during infectious disease outbreaks.
Immunological changes during pregnancy may affect
the risk of developing severe complications in
COVID-19 patients.1 Although the majority of moth-
ers do not develop any major complications, an
increasing body of evidence revealed that SARS-
CoV-2 infection in pregnant women can cause miscar-
riage, severe maternal morbidity and preterm delivery.
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Nevertheless, there is still considerable controversy
about the impact of SARS-CoV-2 infection on preg-
nant women and the fetus. Recent studies report
SARS-CoV-2 viral particles in breast milk, placental
infection with the associated inflammatory changes
demonstrated by immunohistochemistry and high
viral load, and following by neonatal viremia.2
Careful monitoring of pregnancies with COVID-19
and measures to prevent neonatal infection are war-
ranted. Some authors recommend universal screening
for SARS-CoV-2 infection in pregnant women at the
time of delivery or during pregnancy. Currently, the
reverse-transcription polymerase chain reaction
(RT-PCR) on respiratory samples are the gold stan-
dard for the diagnosis of active SARS-CoV-2 infection.
Unfortunately, RT-PCR is time-consuming and
requires specialized operators. However, easy to per-
form, fast and low-cost immunochromatographic
IgM/IgG rapid antibody tests have been suggested as
an efficient screening tool during pregnancy.
Materials and methods
We analysed the clinical performance during pregnancy
of a lateral-flow immunochromatographic assay (ICA)
for qualitative detection of SARS-CoV-2 IgG/IgM
antibodies (Wondfo SARS-CoV-2 Antibody Test,
Guangzhou Wondfo Biotech Co., Guangzhou,
China). Between April 27 and May 29 2020, we per-
formed a universal screening including 169 pregnant
women who were either at 36weeks of gestation or
had COVID-19 symptoms in the third trimester. ICA
was performed according to manufacturer’s instruc-
tion, was carried out by a healthy care professional,
the fingerstick whole blood specimen has been applied
to the test by hanging drops and any band intensity was
considered as a positive result. Fourteen patients had
positive ICA results. Almost half of them (57.1%)
reported having presented in the previous weeks mild-
symptoms (Table 1). Active infection was ruled out by
negative RT-PCR results (Abbott RealTime SARS-
CoV-2 Assay, Abbott Molecular, Abbott Park, IL,
USA) from nasopharyngeal swabs. ICA results were
also confirmed by chemiluminescent microparticle
immunoassays (CMIA) for quantitative detection of
SARS-CoV-2 IgG (IgG-CMIA; SARS-CoV-2 IgG
Assay, Abbott Laboratories Ireland, Dublin, Ireland)
and IgMþIgA antibodies (IgMþIgA-CLIA; COVID-
19 VIRCLIA IgMþIgA, Vircell Microbiologists,
Granada, Spain) as the gold standard.3 The maternal
blood was taken with vacutainer in a tube without anti-
coagulant and has been allowed to clot. The samples
were centrifuged and were determined on the same day.
A signal of-cut-off (S/CO) index >1.4 were considered
positive for IgG. IgMþIgA samples with a S/CO index
less than 0.4 were considered negative samples, those
with a S/CO index more than 0.6 were considered pos-
itive and samples with a S/CO ranging from 0.4 to 0.6
were interpreted as grey zone.
Results
According to the gold standard results, a total of 7 out
of 14 (50%) patients were considered true positive ICA
tests. Six patients were directly positive for IgG-CMIA.
Additionally, one case (number 10) initially presented
an uncertain result for IgMþIgA-CLIA with negative
IgG-CLIA, hence she was considered as recent infec-
tion, as two weeks later she finally had SARS-CoV-2
positive IgG-CLIA (Table 1). The remaining seven
patients tested negative for both IgG-CMIA and
IgMþIgA-CLIA, and therefore were considered ICA
false-positive results. It is important to note that, in
contrast with the previously described case number
10, cases number 6 and number 12 were considered
as false-positive ICA results, as after being initially pos-
itive for IgMþIgA-CLIA (S/Co index 1.1 and 1.09,
respectively) but negative for IgG-CMIA, both
IgMþIgA-CLIA and IgG-CMIA assays were negative
two weeks later (Table 1). Recent studies suggest that
humoral immunity against SARS-CoV-2 may not be
long lasting in persons with mild illness. We evaluated
this possibility in cases number 6 and number 12, as in
both patients levels of IgMþIgA and IgG decreased
between test. However, they never presented positive
results for IgG-CMIA or any symptoms or signs of
SARS-CoV-2 infection.
Discussion
Although since the beginning of this pandemic RT-
PCR has been used to confirm diagnosis of SARS-
CoV-2, serological assays can play an important role
in the management of virus infection. Serologic tests
detect waning or past SARS-CoV-2 virus infection
indirectly by measuring the host humoral immune
response to the virus. A meta-analysis of diagnostic
performance of serological test in general population
yielded a sensitivity of 82% (95%CI: 75–88%) for IgM,
and 85% for IgG (95%CI: 73–93%).4 The fact that
both RT-PCR and serologic assays, need to be deter-
minate by a clinical laboratory, make interesting the
evaluation of the point of care testing as the ICA
rapid test.
It should be noted that as pandemic progresses, the
value of diagnostic testing for SARS-CoV-2 has
enhanced. We considered our available technology as
gold standard but virus neutralization remains the gold
standard for determining antibody efficacy. Although,
this is currently not available. For future studies, it
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would be helpful to compare different immunoassay
for SARS-CoV-2 antibodies in pregnant population.
Newly, lateral-flow immunochromatographic assay
in non-pregnant patients has shown a moderate sensi-
tivity (84.4%) and high specificity (98.6%).5 In con-
trast, we observed in our series of cases a positive
predictive value of 50% with a false positive rate of
50% in pregnant women. Unfortunately, we could
not evaluate the false-negative rate in our study.
However, false-positive results may have a detrimental
effect on pregnant patients, such as false security
awareness increasing the risk of infection, unnecessary
treatment, anxiety or depression.
A false-positive result by ICA test in pregnant
women may be explained by several factors.
Rheumatoid factors, antinuclear and heterophile anti-
bodies are known to interfere with rapid antibody tests.
Moreover, cross-react with various agents such as
influenza-A, respiratory syncytial virus or other coro-
naviruses have been reported.6
The complexity of the immunology of pregnancy
makes it hard to interpret the test results. If there is
any clinical suspicion of discordance between the clin-
ical and the laboratory data, an attempt should be
made to resolve the difference. The CMIA can mini-
mize these interferences by careful choices of reagents,
dilution, depletion or blocking, while rapid antibody
tests cannot.
It is important to emphasize that the false positive
rate depends on the prevalence of disease in the popu-
lation. Instead, the sensitivity and specificity of the
diagnostics test are independent of the prevalence.
Thus, decisions made in low prevalence settings must
not be automatically extrapolated to settings with high
disease prevalence.
This study has several limitations. The first limita-
tion is the small number of participants and the inabil-
ity to confirm all ICA test by CMIA. It would have
been interesting to perform ICA test and CMIA test on
the same sample or at least on the same type of sample.
In fact, recently it has been demonstrated significantly
superior sensitivity with serum (80%) than with whole
blood (57%) in ICA test.5 However, while serum show
better results than whole blood, serum samples have
the disadvantage of requiring additional laboratory
material. Despite these constrains, our study is
designed to be a tool for others professionals in clinical
practice.
To our knowledge, this is the first population-based
study to evaluate a SARS-CoV-2 rapid antibody test in
pregnant women. Our data suggest that although
immunochromatographic assay for qualitative detec-
tion of SARS-CoV-2 IgG/IgM antibodies may be a
fast and profitable screening tool, they have a high
false positive rate in pregnant women. Thus, ICA anti-
bodies SARS-CoV-2 tests must be verified by other test
methods such as chemiluminescent microparticle
immunoassays in pregnant patients.
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